Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
Medstar Health Research Institute
Study ID
NCT00006682
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • docetaxel — DRUG
    Docetaxel 70mg/m2 on day 1 of every 21-day cycle
  • vinorelbine ditartrate — DRUG
    Navelbine 20mg/m2 on Day 1 and D8 of a 21-day cycle

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of vinorelbine combined with docetaxel in treating women who have metastatic breast cancer.

Key Dates

Start date
Feb 29, 2000
Status verified
May 2001
Primary completion
Jan 22, 2002
Completion
Jan 22, 2002

Study Design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Locations (2)

FacilityCityStateZIPSite coordinators
Washington Cancer InstituteWashington D.C.District of Columbia20010-
Washington Hospital CenterWashington D.C.District of Columbia20010-

Find similar trials in Washington D.C., DC

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Washington Cancer Institute· Washington D.C., DCWashington Hospital Center· Washington D.C., DC

Related Studies